Argenx announces u.s. food and drug administration (fda) approval of vyvgart™ (efgartigimod alfa-fcab) in generalized myasthenia gravis

Breda, netherlands--(business wire)--regulatory news: argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the u.s. food and drug administration (fda) has approved vyvgart™ (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gmg) in adult patients who are anti-acetylcholine receptor (achr) antibody positive. these patients represent appro
ARGX Ratings Summary
ARGX Quant Ranking